Unbiased	O
estimation	O
in	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
with	O
unequal	O
treatment	O
effect	O
variances	O
and	O
hypothesis	O
‐	O
driven	O
selection	O
rules	O

Seamless	O
phase	O
II	O
/	O
III	O
clinical	O
trials	O
offer	O
an	O
efficient	O
way	O
to	O
select	O
an	O
experimental	O
treatment	O
and	O
perform	O
confirmatory	O
analysis	O
within	O
a	O
single	O
trial	O
.	O

However	O
,	O
combining	O
the	O
data	O
from	O
both	O
stages	O
in	O
the	O
final	O
analysis	O
can	O
induce	O
bias	O
into	O
the	O
estimates	O
of	O
treatment	O
effects	O
.	O

Methods	O
for	O
bias	O
adjustment	O
developed	O
thus	O
far	O
have	O
made	O
restrictive	O
assumptions	O
about	O
the	O
design	O
and	O
selection	O
rules	O
followed	O
.	O

In	O
order	O
to	O
address	O
these	O
shortcomings	O
,	O
we	O
apply	O
recent	O
methodological	O
advances	O
to	O
derive	O
the	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
for	O
two	O
‐	O
stage	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
.	O

Our	O
framework	O
allows	O
for	O
the	O
precision	O
of	O
the	O
treatment	O
arm	O
estimates	O
to	O
take	O
arbitrary	O
values	O
,	O
can	O
be	O
utilised	O
for	O
all	O
treatments	O
that	O
are	O
taken	O
forward	O
to	O
phase	O
III	O
and	O
is	O
applicable	O
when	O
the	O
decision	O
to	O
select	O
or	O
drop	O
treatment	O
arms	O
is	O
driven	O
by	O
a	O
multiplicity	O
‐	O
adjusted	O
hypothesis	O
testing	O
procedure	O
.	O
©	O
2016	O
The	O
Authors	O
.	O

Statistics	O
in	O
Medicine	O
Published	O
by	O
John	O
Wiley	O
&	O
Sons	O
Ltd	O
.	O

Unbiased	O
estimation	O
in	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
with	O
unequal	O
treatment	O
effect	O
variances	O
and	O
hypothesis	O
‐	O
driven	O
selection	O
rules	O

Introduction	O

Seamless	O
phase	O
II	O
/	O
III	O
designs	O
are	O
key	O
examples	O
of	O
adaptive	O
clinical	O
trials	O
where	O
data	O
from	O
a	O
learning	O
phase	O
and	O
a	O
confirmatory	O
phase	O
are	O
combined	O
to	O
promote	O
efficient	O
drug	O
development	O
.	O

Typically	O
,	O
such	O
trials	O
will	O
have	O
two	O
stages	O
separated	O
by	O
an	O
interim	O
analysis	O
.	O

In	O
stage	O
1	O
,	O
which	O
resembles	O
a	O
traditional	O
phase	O
II	O
trial	O
,	O
multiple	O
experimental	O
treatments	O
or	O
drug	O
doses	O
are	O
simultaneously	O
compared	O
against	O
a	O
control	O
.	O

The	O
most	O
promising	O
candidates	O
are	O
then	O
selected	O
for	O
confirmatory	O
analysis	O
in	O
stage	O
2	O
,	O
which	O
corresponds	O
to	O
a	O
phase	O
III	O
trial	O
.	O

Recent	O
examples	O
of	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
in	O
clinical	O
practice	O
include	O
dose	O
selection	O
for	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disorder	I-DS
1	O
,	O
acute	B-DS
myocardial	I-DS
infarction	I-DS
2	O
and	O
treatment	O
selection	O
for	O
colorectal	B-DS
cancer	I-DS
3	O
.	O

Regulatory	O
guidance	O
dealing	O
with	O
such	O
adaptive	O
trial	O
designs	O
has	O
been	O
produced	O
in	O
Europe	O
by	O
the	O
European	O
Medicines	O
Agency	O
4	O
and	O
in	O
the	O
USA	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
5	O
.	O

Unlike	O
the	O
classical	O
approach	O
where	O
only	O
phase	O
III	O
patients	O
contribute	O
to	O
the	O
confirmatory	O
analysis	O
,	O
in	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
,	O
the	O
final	O
analysis	O
utilises	O
data	O
from	O
both	O
stages	O
.	O

Whilst	O
combining	O
the	O
data	O
is	O
efficient	O
in	O
terms	O
of	O
time	O
and	O
resources	O
(	O
and	O
of	O
course	O
in	O
a	O
purely	O
statistical	O
sense	O
too	O
),	O
it	O
can	O
inflate	O
the	O
type	O
I	O
error	O
of	O
hypothesis	O
tests	O
and	O
induce	O
bias	O
into	O
the	O
naïve	O
estimates	O
of	O
treatment	O
effect	O
,	O
because	O
of	O
the	O
dual	O
influence	O
of	O
multiplicity	O
and	O
selection	O
6	O
.	O

In	O
this	O
paper	O
,	O
we	O
consider	O
point	O
estimation	O
of	O
the	O
treatment	O
effects	O
.	O

In	O
particular	O
,	O
our	O
focus	O
is	O
on	O
conditionally	O
unbiased	O
estimation	O
using	O
the	O
method	O
of	O
Rao	O
–	O
Blackwellization	O
.	O

Briefly	O
,	O
this	O
involves	O
taking	O
the	O
unbiased	O
stage	O
2	O
data	O
and	O
conditioning	O
on	O
a	O
complete	O
,	O
sufficient	O
statistic	O
.	O

The	O
resulting	O
estimator	O
is	O
the	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
(	O
UMVCUE	O
).	O

Our	O
key	O
starting	O
point	O
in	O
deriving	O
the	O
UMVCUE	O
for	O
the	O
treatment	O
effect	O
is	O
the	O
paper	O
by	O
Kimani	O
et	O
al	O
.	O
7	O
.	O

Building	O
on	O
the	O
seminal	O
framework	O
of	O
Cohen	O
and	O
Sackorwitz	O
8	O
,	O
Kimani	O
et	O
al	O
.	O
derived	O
the	O
UMVCUEs	O
for	O
the	O
means	O
of	O
the	O
selected	O
and	O
control	O
treatments	O
separately	O
and	O
then	O
took	O
the	O
difference	O
to	O
give	O
an	O
unbiased	O
estimator	O
for	O
the	O
treatment	O
difference	O
.	O

However	O
,	O
a	O
number	O
of	O
limitations	O
to	O
this	O
approach	O
currently	O
exist	O
.	O

Firstly	O
,	O
the	O
methodology	O
does	O
not	O
try	O
to	O
explicitly	O
take	O
into	O
account	O
differing	O
treatment	O
effect	O
variances	O
.	O

Hence	O
,	O
if	O
treatment	O
selection	O
is	O
based	O
on	O
standardised	O
differences	O
,	O
the	O
estimator	O
will	O
not	O
necessarily	O
be	O
unbiased	O
when	O
the	O
treatment	O
effect	O
variances	O
are	O
unequal	O
.	O

Many	O
other	O
authors	O
have	O
also	O
used	O
the	O
convention	O
of	O
equal	O
variances	O
in	O
order	O
to	O
derive	O
their	O
results	O
9	O
,	O
10	O
,	O
11	O
,	O
12	O
.	O

This	O
allows	O
the	O
information	O
from	O
the	O
treatment	O
and	O
control	O
arms	O
at	O
phases	O
II	O
and	O
III	O
to	O
be	O
separated	O
,	O
and	O
all	O
estimates	O
can	O
be	O
assumed	O
to	O
be	O
independent	O
.	O

However	O
,	O
there	O
are	O
many	O
reasons	O
why	O
differences	O
in	O
the	O
treatment	O
effect	O
variances	O
may	O
occur	O
,	O
even	O
if	O
this	O
was	O
not	O
planned	O
at	O
the	O
outset	O
.	O

For	O
example	O
,	O
there	O
may	O
be	O
unequal	O
drop	O
out	O
across	O
arms	O
,	O
or	O
there	O
simply	O
may	O
be	O
true	O
differences	O
between	O
the	O
variance	O
of	O
patient	O
outcomes	O
for	O
different	O
experimental	O
treatments	O
.	O

Secondly	O
,	O
the	O
estimator	O
is	O
only	O
for	O
the	O
treatment	O
with	O
the	O
largest	O
treatment	O
difference	O
.	O

However	O
,	O
we	O
may	O
be	O
interested	O
in	O
estimating	O
the	O
treatment	O
difference	O
for	O
several	O
treatments	O
,	O
for	O
example	O
,	O
when	O
the	O
decision	O
to	O
select	O
/	O
drop	O
treatments	O
is	O
driven	O
by	O
a	O
formal	O
hypothesis	O
testing	O
procedure	O
.	O

We	O
note	O
that	O
formulae	O
that	O
are	O
applicable	O
to	O
this	O
setting	O
have	O
been	O
derived	O
by	O
Bowden	O
and	O
Glimm	O
10	O
,	O
but	O
for	O
different	O
ranking	O
and	O
selection	O
rules	O
to	O
those	O
considered	O
in	O
this	O
paper	O
.	O

In	O
practice	O
,	O
and	O
as	O
for	O
any	O
confirmatory	O
trial	O
,	O
hypothesis	O
testing	O
(	O
with	O
rigid	O
type	O
I	O
error	O
control	O
)	O
will	O
be	O
the	O
primary	O
focus	O
of	O
a	O
seamless	O
phase	O
II	O
/	O
III	O
trial	O
,	O
with	O
estimation	O
being	O
an	O
important	O
but	O
secondary	O
target	O
.	O

For	O
a	O
comprehensive	O
overview	O
of	O
the	O
methodology	O
for	O
hypothesis	O
testing	O
in	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
,	O
we	O
refer	O
the	O
reader	O
to	O
the	O
reviews	O
of	O
Bretz	O
et	O
al	O
.	O
13	O
and	O
Stallard	O
and	O
Todd	O
14	O
.	O

In	O
this	O
paper	O
,	O
we	O
aim	O
to	O
address	O
these	O
limitations	O
,	O
by	O
transferring	O
recent	O
methodological	O
advancements	O
in	O
UMVCUEs	O
for	O
multivariate	O
normal	O
outcomes	O
proposed	O
by	O
Robertson	O
et	O
al	O
.	O
15	O
to	O
the	O
seamless	O
phase	O
II	O
/	O
III	O
setting	O
.	O

We	O
derive	O
formulae	O
that	O
are	O
applicable	O
in	O
full	O
generality	O
for	O
the	O
jth	O
‐	O
ranked	O
treatment	O
where	O
the	O
precision	O
of	O
treatment	O
arm	O
estimates	O
can	O
take	O
arbitrary	O
values	O
.	O

The	O
rest	O
of	O
the	O
paper	O
is	O
organised	O
as	O
follows	O
.	O

In	O
Section	O
2	O
,	O
we	O
describe	O
the	O
set	O
‐	O
up	O
and	O
notation	O
,	O
derive	O
the	O
UMVCUE	O
for	O
the	O
maximum	O
treatment	O
difference	O
and	O
compare	O
it	O
analytically	O
with	O
the	O
Kimani	O
et	O
al	O
.	O
estimator	O
.	O

We	O
carry	O
out	O
a	O
simulation	O
study	O
in	O
Section	O
3	O
to	O
compare	O
the	O
bias	O
and	O
mean	O
square	O
error	O
of	O
the	O
Kimani	O
et	O
al	O
.	O
estimator	O
and	O
our	O
UMVCUE	O
in	O
a	O
variety	O
of	O
trial	O
settings	O
.	O

Section	O
4	O
describes	O
how	O
our	O
UMVCUE	O
can	O
be	O
used	O
in	O
the	O
context	O
of	O
a	O
seamless	O
phase	O
II	O
/	O
III	O
trial	O
where	O
a	O
multiplicity	O
adjusted	O
hypothesis	O
procedure	O
drives	O
the	O
design	O
and	O
is	O
illustrated	O
with	O
a	O
simple	O
practical	O
example	O
.	O

We	O
discuss	O
all	O
of	O
our	O
results	O
in	O
Section	O
5	O
and	O
consider	O
future	O
avenues	O
of	O
research	O
.	O

Framework	O
for	O
the	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O

We	O
use	O
the	O
adaptive	O
seamless	O
design	O
(	O
ASD	O
)	O
setting	O
of	O
Kimani	O
et	O
al	O
.	O
7	O
as	O
our	O
starting	O
point	O
.	O

Consider	O
an	O
ASD	O
with	O
two	O
stages	O
,	O
where	O
stage	O
1	O
is	O
used	O
to	O
select	O
the	O
most	O
promising	O
treatment	O
and	O
stage	O
2	O
is	O
used	O
for	O
confirmatory	O
analysis	O
.	O

Let	O
K	O
(	O
≥	O
2	O
)	O
denote	O
the	O
number	O
of	O
experimental	O
treatments	O
tested	O
in	O
stage	O
1	O
for	O
comparison	O
with	O
the	O
control	O
.	O

The	O
treatment	O
that	O
shows	O
the	O
highest	O
standardised	O
treatment	O
difference	O
(	O
as	O
defined	O
in	O
the	O
succeeding	O
text	O
)	O
in	O
stage	O
1	O
is	O
then	O
selected	O
to	O
continue	O
to	O
stage	O
2	O
,	O
along	O
with	O
the	O
control	O
.	O

We	O
now	O
allow	O
for	O
the	O
treatment	O
arm	O
estimates	O
to	O
have	O
unequal	O
variances	O
.	O

Let	O
n	O
1i	O
denote	O
the	O
number	O
of	O
subjects	O
allocated	O
to	O
treatment	O
i	O
(	O
i	O
=	O
0	O
,	O
1	O
,…,	O
K	O
)	O
in	O
stage	O
1	O
,	O
where	O
i	O
=	O
0	O
corresponds	O
to	O
the	O
control	O
treatment	O
.	O

We	O
assume	O
that	O
the	O
stage	O
1	O
sample	O
mean	O
for	O
treatment	O
i	O
,	O
denoted	O
X	O
i	O
,	O
is	O
normally	O
distributed	O
with	O
unknown	O
mean	O
μ	O
i	O
and	O
known	O
variance	O
σ1i2	O
.	O

As	O
an	O
example	O
,	O
if	O
we	O
also	O
assume	O
that	O
there	O
is	O
a	O
known	O
common	O
variance	O
σ	O
2	O
across	O
the	O
treatment	O
groups	O
,	O
then	O
σ1i2	O
=	O
σ2	O
/	O
n1i	O
.	O

At	O
the	O
end	O
of	O
stage	O
1	O
,	O
we	O
rank	O
the	O
treatments	O
according	O
to	O
their	O
standardised	O
treatment	O
difference	O
.	O

More	O
explicitly	O
,	O
we	O
rank	O
treatment	O
i	O
above	O
treatment	O
j	O
if	O
(	O
1	O
)	O
Xi	O
−	O
X0Var	O
(	O
Xi	O
−	O
X0	O
)>	O
Xj	O
−	O
X0Var	O
(	O
Xj	O
−	O
X0	O
)⇒	O
Xi	O
−	O
X0σ1i2	O
+	O
σ102	O
>	O
Xj	O
−	O
X0σ1j2	O
+	O
σ102	O
.	O

In	O
contrast	O
,	O
in	O
the	O
Kimani	O
et	O
al	O
.	O
setting	O
,	O
we	O
rank	O
the	O
treatments	O
by	O
the	O
stage	O
1	O
sample	O
means	O
,	O
and	O
so	O
treatment	O
i	O
is	O
ranked	O
above	O
treatment	O
j	O
if	O
X	O
i	O
>	O
X	O
j	O
.	O

Note	O
that	O
if	O
we	O
have	O
a	O
common	O
stage	O
1	O
variance	O
,	O
that	O
is	O
,	O
σ	O
1i	O
=	O
σ	O
1	O
for	O
i	O
=	O
1	O
,…,	O
K	O
,	O
then	O
the	O
two	O
ranking	O
rules	O
are	O
the	O
same	O
,	O
because	O
when	O
ranking	O
by	O
standardised	O
treatment	O
difference	O
,	O
the	O
denominator	O
and	O
control	O
data	O
X	O
0	O
can	O
be	O
ignored	O
.	O

We	O
let	O
the	O
treatment	O
with	O
the	O
highest	O
ranking	O
be	O
denoted	O
S	O
(	O
S	O
∈{	O
1	O
,…,	O
K	O
}),	O
where	O
S	O
is	O
a	O
random	O
variable	O
.	O

We	O
also	O
allow	O
early	O
stopping	O
of	O
the	O
trial	O
for	O
futility	O
:	O
the	O
trial	O
continues	O
to	O
stage	O
2	O
if	O
XS	O
−	O
X0σ1S2	O
+	O
σ102	O
>	O
b	O
,	O
where	O
b	O
is	O
a	O
(	O
pre	O
‐	O
specified	O
and	O
constant	O
)	O
futility	O
boundary	O
.	O

For	O
notational	O
convenience	O
,	O
let	O
Θi	O
=	O
X	O
i	O
−	O
X	O
0	O
denote	O
the	O
stage	O
1	O
sample	O
mean	O
treatment	O
difference	O
for	O
treatment	O
i	O
(	O
i	O
=	O
1	O
,…,	O
K	O
)	O
and	O
define	O
λi	O
=	O
1	O
/	O
σ1i2	O
+	O
σ102	O
(	O
i	O
=	O
1	O
,…,	O
K	O
).	O

Then	O
treatment	O
i	O
is	O
ranked	O
above	O
treatment	O
j	O
if	O
λ	O
iΘi	O
>	O
λ	O
jΘj	O
.	O

As	O
well	O
,	O
the	O
futility	O
boundary	O
implies	O
that	O
λ	O
SΘS	O
>	O
b	O
in	O
order	O
for	O
the	O
trial	O
to	O
continue	O
to	O
stage	O
2	O
.	O

If	O
the	O
trial	O
continues	O
to	O
stage	O
2	O
,	O
then	O
let	O
n	O
2i	O
denote	O
the	O
number	O
of	O
subjects	O
allocated	O
to	O
treatment	O
i	O
(	O
i	O
=	O
0	O
,	O
S	O
).	O

We	O
assume	O
that	O
the	O
stage	O
2	O
sample	O
means	O
,	O
denoted	O
Y	O
i	O
,	O
follow	O
a	O
N	O
(	O
μi	O
,	O
σ2i2	O
)	O
distribution	O
.	O

As	O
before	O
,	O
if	O
we	O
also	O
assume	O
a	O
known	O
common	O
variance	O
σ	O
2	O
,	O
then	O
σ2i2	O
=	O
σ2	O
/	O
n2i	O
.	O

We	O
can	O
define	O
the	O
selection	O
time	O
for	O
treatment	O
i	O
(	O
i	O
=	O
0	O
,	O
S	O
)	O
as	O
ti	O
=	O
σ2i2	O
/(	O
σ1i2	O
+	O
σ2i2	O
).	O

Hence	O
,	O
the	O
sample	O
mean	O
from	O
the	O
two	O
stages	O
for	O
the	O
control	O
is	O
Z	O
0	O
,	O
MLE	O
=	O
t	O
0	O
X	O
0	O
+(	O
1	O
−	O
t	O
0	O
)	O
Y	O
0	O
and	O
similarly	O
Z	O
S	O
,	O
MLE	O
=	O
t	O
S	O
X	O
S	O
+(	O
1	O
−	O
t	O
S	O
)	O
Y	O
S	O
for	O
the	O
selected	O
treatment	O
.	O

After	O
the	O
trial	O
is	O
completed	O
,	O
the	O
aim	O
is	O
to	O
estimate	O
the	O
treatment	O
difference	O
θ	O
S	O
=	O
μ	O
S	O
−	O
μ	O
0	O
.	O

As	O
Kimani	O
et	O
al	O
.	O
note	O
,	O
the	O
maximum	O
likelihood	O
estimator	O
(	O
MLE	O
)	O
for	O
θ	O
S	O
is	O
D	O
S	O
,	O
MLE	O
=	O
Z	O
S	O
,	O
MLE	O
−	O
Z	O
0	O
,	O
MLE	O
.	O

This	O
estimator	O
will	O
likely	O
be	O
biased	O
,	O
because	O
it	O
does	O
not	O
take	O
into	O
account	O
the	O
selection	O
rules	O
.	O

An	O
unbiased	O
estimator	O
can	O
easily	O
be	O
found	O
by	O
just	O
using	O
the	O
stage	O
2	O
data	O
,	O
because	O
Y	O
S	O
and	O
Y	O
0	O
are	O
unbiased	O
estimators	O
for	O
μ	O
S	O
and	O
μ	O
0	O
,	O
respectively	O
.	O

Hence	O
,	O
the	O
sample	O
difference	O
Y	O
=	O
Y	O
S	O
−	O
Y	O
0	O
is	O
an	O
unbiased	O
estimator	O
for	O
θ	O
S	O
.	O

However	O
,	O
this	O
estimator	O
will	O
be	O
inefficient	O
because	O
it	O
does	O
not	O
use	O
the	O
stage	O
1	O
data	O
.	O

Calculating	O
the	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O

Using	O
the	O
theory	O
from	O
the	O
general	O
multivariate	O
normal	O
setting	O
15	O
,	O
we	O
derive	O
the	O
UMVCUE	O
for	O
this	O
framework	O
.	O

The	O
stage	O
1	O
sample	O
mean	O
treatment	O
differences	O
Θi	O
=	O
X	O
i	O
−	O
X	O
0	O
are	O
normally	O
distributed	O
:	O
Θi	O
∼	O
Nμi	O
−	O
μ0	O
,	O
σ1i2	O
+	O
σ102	O
.	O

Because	O
Θ	O
=	O
(	O
Θ1	O
,…,	O
ΘK	O
)	O
is	O
a	O
linear	O
transformation	O
of	O
X	O
=	O
(	O
X	O
0	O
,	O
X	O
1	O
,…,	O
X	O
K	O
),	O
then	O
Θ	O
follows	O
a	O
multivariate	O
normal	O
distribution	O
with	O
mean	O
θ	O
=	O
(	O
θ	O
1	O
,…,	O
θ	O
K	O
)	O
and	O
covariance	O
matrix	O
Σ	O
,	O
where	O
θ	O
i	O
=	O
μ	O
i	O
−	O
μ	O
0	O
and	O
Σij	O
=	O
Cov	O
(	O
Θi	O
,	O
Θj	O
).	O

Hence	O
,	O
Σii	O
=	O
σ1i2	O
+	O
σ102i	O
∈{	O
1	O
,…,	O
K	O
}	O
Σij	O
=	O
σ102i	O
,	O
j	O
∈{	O
1	O
,…,	O
K	O
},	O
i	O
≠	O
j	O
.	O
The	O
stage	O
2	O
sample	O
mean	O
treatment	O
difference	O
Y	O
=	O
Y	O
S	O
−	O
Y	O
0	O
is	O
also	O
normally	O
distributed	O
with	O
Y	O
∼	O
N	O
(	O
μS	O
−	O
μ0	O
,	O
σ202	O
+	O
σ2S2	O
).	O

Let	O
Q	O
be	O
the	O
event	O
{	O
Θ	O
:	O
λ	O
1Θ1	O
>	O
λ	O
2Θ2	O
>⋯>	O
λ	O
KΘK	O
,	O
λ	O
1Θ1	O
>	O
b	O
},	O
which	O
implies	O
that	O
the	O
trial	O
continues	O
to	O
stage	O
2	O
and	O
that	O
treatment	O
i	O
has	O
rank	O
i	O
,	O
with	O
S	O
=	O
1	O
.	O

Without	O
loss	O
of	O
generality	O
,	O
we	O
condition	O
on	O
Q	O
for	O
the	O
remainder	O
of	O
this	O
section	O
.	O

For	O
notational	O
convenience	O
,	O
let	O
ν2	O
=	O
σ102	O
+	O
σ112	O
and	O
τ2	O
=	O
σ202	O
+	O
σ212	O
.	O

Then	O
the	O
statistics	O
Z	O
=	O
(	O
Z	O
1	O
,…,	O
Z	O
K	O
)	O
are	O
sufficient	O
and	O
complete	O
for	O
θ	O
,	O
where	O
(	O
2	O
)	O
Z1	O
=	O
Θ1	O
+	O
ν2τ2YZi	O
=	O
Θi	O
+	O
σ102τ2Yi	O
=	O
2	O
,…,	O
K	O
.	O

Using	O
the	O
notation	O
defined	O
previously	O
,	O
we	O
have	O
the	O
following	O
form	O
for	O
the	O
UMVCUE	O
,	O
with	O
a	O
proof	O
provided	O
in	O
Appendix	O
A	O
.	O
1	O
.	O
Theorem	O
2	O
.	O
1The	O
UMVCUE	O
for	O
θ	O
1	O
=	O
μ	O
1	O
−	O
μ	O
0	O
given	O
Q	O
is	O
(	O
3	O
)	O
Û	O
=	O
τ2Z1ν2	O
+	O
τ2	O
−	O
τ2ν2	O
+	O
τ2ϕ	O
(	O
W1	O
)−	O
ϕ	O
(	O
W2	O
)	O
Φ	O
(	O
W1	O
)−	O
Φ	O
(	O
W2	O
),	O
where	O
Wi	O
=	O
kiν2	O
+	O
τ2τ2	O
−	O
Z1ν2	O
+	O
τ2fori	O
=	O
1	O
,	O
2	O
;	O
k1	O
=	O
min	O
(	O
A1	O
,	O
A2	O
,	O
A3	O
),	O
k2	O
=	O
max	O
(	O
A4	O
,	O
A5	O
),	O
A1	O
=	O
τ2ν2Z1	O
−	O
bλ1	O
,	O
A2	O
=	O
τ2λ1Z1	O
−	O
λ2Z2σ102λ1	O
−	O
λ2	O
+	O
λ1σ112	O
:	O
λ1σ112	O
>	O
λ2	O
−	O
λ1σ102	O
,	O
A3	O
=	O
τ2λiZi	O
−	O
λi	O
+	O
1Zi	O
+	O
1σ102λi	O
−	O
λi	O
+	O
1	O
:	O
σ1	O
,	O
i	O
+	O
12	O
>	O
σ1i2	O
;	O
i	O
=	O
2	O
,…,	O
K	O
−	O
1	O
,	O
A4	O
=	O
τ2λ1Z1	O
−	O
λ2Z2σ102λ1	O
−	O
λ2	O
+	O
λ1σ112	O
:	O
λ1σ112	O
<	O
λ2	O
−	O
λ1σ102	O
,	O
A5	O
=	O
τ2λiZi	O
−	O
λi	O
+	O
1Zi	O
+	O
1σ102λi	O
−	O
λi	O
+	O
1	O
:	O
σ1	O
,	O
i	O
+	O
12	O
<	O
σ1i2	O
;	O
i	O
=	O
2	O
,…,	O
K	O
−	O
1	O
,	O
and	O
we	O
define	O
min	O
({∅})	O
=+	O
∞	O
and	O
max	O
({∅})	O
=−	O
∞.	O

Note	O
that	O
the	O
first	O
term	O
in	O
expression	O
(	O
3	O
),	O
namely	O
,	O
τ2Z1ν2	O
+	O
τ2	O
,	O
is	O
equal	O
to	O
the	O
MLE	O
D	O
S	O
,	O
MLE	O
.	O

Comparison	O
with	O
the	O
estimator	O
of	O
Kimani	O
et	O
al	O
.	O

Suppose	O
we	O
set	O
σ1i2	O
=	O
σ12	O
(	O
for	O
i	O
=	O
0	O
,	O
1	O
,…,	O
K	O
)	O
and	O
σ2i2	O
=	O
σ22	O
(	O
for	O
i	O
=	O
0	O
,	O
1	O
).	O

We	O
then	O
recover	O
the	O
setting	O
of	O
Kimani	O
et	O
al	O
.	O
7	O
,	O
so	O
we	O
can	O
compare	O
our	O
results	O
.	O

In	O
this	O
case	O
,	O
ranking	O
by	O
standardised	O
treatment	O
difference	O
reduces	O
down	O
to	O
ranking	O
by	O
the	O
stage	O
1	O
sample	O
mean	O
,	O
in	O
the	O
sense	O
that	O
they	O
always	O
select	O
the	O
same	O
treatment	O
.	O

Kimani	O
et	O
al	O
.	O
derived	O
the	O
following	O
unbiased	O
estimator	O
for	O
θ	O
1	O
=	O
μ	O
1	O
−	O
μ	O
0	O
:	O
(	O
4	O
)	O
D1	O
,	O
CHN	O
=	O
Z1	O
,	O
CHN	O
−	O
Z0	O
,	O
CHN	O
=	O
σ22X1	O
+	O
σ12Y1σ12	O
+	O
σ22	O
−	O
σ22σ12	O
+	O
σ22ϕ	O
(	O
WB	O
)	O
Φ	O
(	O
WB	O
)−	O
σ22X0	O
+	O
σ12Y0σ12	O
+	O
σ22	O
+	O
σ22σ12	O
+	O
σ22ϕWB1ΦWB1	O
=	O
σ22	O
(	O
X1	O
−	O
X0	O
)+	O
σ12	O
(	O
Y1	O
−	O
Y0	O
)	O
σ12	O
+	O
σ22	O
−	O
σ22σ12	O
+	O
σ22ϕ	O
(	O
WB	O
)	O
Φ	O
(	O
WB	O
)+	O
ϕWB1ΦWB1	O
,	O
where	O
WB	O
=	O
σ12	O
+	O
σ22σ12σ22X1	O
+	O
σ12Y1σ12	O
+	O
σ22	O
−	O
max	O
{	O
X0	O
+	O
bσ12	O
,	O
X2	O
}	O
WB1	O
=	O
σ12	O
+	O
σ22σ12X1	O
−	O
bσ12	O
−	O
σ22X0	O
+	O
σ12Y0σ12	O
+	O
σ22	O
.	O
As	O
for	O
the	O
UMVCUE	O
derived	O
in	O
Section	O
2	O
,	O
firstly	O
note	O
that	O
σ	O
1	O
,	O
j	O
+	O
1	O
=	O
σ	O
1j	O
=	O
σ	O
1	O
for	O
j	O
=	O
2	O
,…,	O
K	O
−	O
1	O
.	O

Hence	O
,	O
the	O
sets	O
A	O
3	O
and	O
A	O
5	O
are	O
empty	O
in	O
Equation	O
(	O
3	O
).	O

In	O
addition	O
,	O
σ112	O
=	O
σ122	O
⇒	O
λ1	O
=	O
λ2	O
,	O
and	O
hence	O
,	O
A	O
4	O
is	O
also	O
empty	O
.	O

Note	O
also	O
that	O
τ2	O
=	O
2σ22	O
and	O
ν2	O
=	O
2σ12	O
.	O

The	O
sufficient	O
statistics	O
in	O
this	O
case	O
are	O
Z1	O
=	O
Θ1	O
+	O
σ12σ22YZi	O
=	O
Θi	O
+	O
σ122σ22Yi	O
=	O
2	O
,…,	O
K	O
.	O
Hence	O
,	O
the	O
UMVCUE	O
equals	O
(	O
5	O
)	O
Û	O
=	O
σ22Z1σ12	O
+	O
σ22	O
−	O
σ222σ12	O
+	O
σ22ϕ	O
(	O
W	O
)	O
Φ	O
(	O
W	O
)=	O
σ22	O
(	O
X1	O
−	O
X0	O
)+	O
σ12	O
(	O
Y1	O
−	O
Y0	O
)	O
σ12	O
+	O
σ22	O
−	O
σ222σ12	O
+	O
σ22ϕ	O
(	O
W	O
)	O
Φ	O
(	O
W	O
),	O
where	O
W	O
=	O
kσ12	O
+	O
σ22σ222	O
−	O
Z12σ12	O
+	O
σ22	O
,	O
k	O
=	O
min	O
(	O
A1	O
,	O
A2	O
),	O
A1	O
=	O
σ22σ12Z1	O
−	O
bσ12	O
,	O
A2	O
=	O
2σ22σ12	O
(	O
Z1	O
−	O
Z2	O
).	O
Now	O
,	O
we	O
can	O
rewrite	O
W	O
as	O
W	O
=	O
σ12	O
+	O
σ22σ222min2σ22σ12Z1	O
−	O
Z2	O
,	O
σ22σ12Z1	O
−	O
bσ12	O
−	O
Z12σ12	O
+	O
σ22	O
=	O
σ12	O
+	O
σ22σ122σ22Z1σ12	O
+	O
σ22	O
−	O
max2Z2	O
−	O
Z1	O
,	O
bσ12	O
=	O
σ12	O
+	O
σ22σ122σ22X1	O
−	O
X0	O
+	O
σ12Y1	O
−	O
Y0σ12	O
+	O
σ22	O
−	O
max2X2	O
−	O
X1	O
−	O
X1	O
−	O
X0	O
,	O
bσ12	O
.	O
Even	O
for	O
the	O
special	O
case	O
when	O
the	O
two	O
methods	O
always	O
select	O
the	O
same	O
treatment	O
,	O
the	O
estimators	O
are	O
not	O
equal	O
,	O
because	O
the	O
estimators	O
condition	O
on	O
different	O
selection	O
rules	O
and	O
data	O
.	O

We	O
return	O
to	O
this	O
issue	O
in	O
Section	O
3	O
.	O
1	O
.	O
1	O
.	O

Simulation	O
study	O

We	O
now	O
perform	O
a	O
simulation	O
study	O
to	O
explore	O
the	O
bias	O
and	O
mean	O
squared	O
error	O
(	O
MSE	O
)	O
of	O
the	O
estimators	O
described	O
in	O
Section	O
2	O
.	O

Because	O
the	O
performance	O
of	O
the	O
Kimani	O
et	O
al	O
.	O
(	O
D	O
1	O
,	O
CHN	O
),	O
naïve	O
(	O
D	O
1	O
,	O
MLE	O
)	O
and	O
stage	O
2	O
(	O
D	O
1	O
,	O
2	O
)	O
estimators	O
have	O
already	O
been	O
extensively	O
studied	O
in	O
7	O
,	O
we	O
focus	O
on	O
comparing	O
the	O
properties	O
of	O
our	O
UMVCUE	O
with	O
these	O
existing	O
estimators	O
.	O

Equal	O
variances	O

Initially	O
we	O
use	O
the	O
setting	O
of	O
Kimani	O
et	O
al	O
.	O
7	O
,	O
with	O
a	O
common	O
variance	O
σ	O
2	O
,	O
n	O
1i	O
=	O
n	O
1	O
(	O
i	O
=	O
0	O
,	O
1	O
,…,	O
K	O
)	O
and	O
n	O
2i	O
=	O
n	O
2	O
(	O
i	O
=	O
0	O
,	O
1	O
).	O

Hence	O
,	O
the	O
stages	O
1	O
and	O
2	O
variances	O
are	O
all	O
equal	O
,	O
and	O
we	O
can	O
write	O
σ1i2	O
=	O
σ12	O
=	O
σ2	O
/	O
n1	O
and	O
σ2i2	O
=	O
σ22	O
=	O
σ2	O
/	O
n2	O
.	O

Also	O
the	O
selection	O
times	O
t	O
i	O
all	O
equal	O
t	O
=	O
n1n1	O
+	O
n2	O
.	O

In	O
our	O
simulations	O
,	O
we	O
set	O
the	O
common	O
variance	O
σ	O
=	O
1	O
and	O
vary	O
the	O
selection	O
time	O
point	O
t	O
in	O
the	O
interval	O
(	O
0	O
,	O
1	O
).	O

Because	O
the	O
stages	O
1	O
and	O
2	O
sample	O
sizes	O
per	O
arm	O
are	O
equal	O
,	O
we	O
can	O
present	O
the	O
bias	O
and	O
the	O
MSE	O
of	O
the	O
estimators	O
in	O
units	O
of	O
the	O
standard	O
error	O
(	O
SE	O
)	O
2	O
/(	O
n1	O
+	O
n2	O
).	O

This	O
is	O
the	O
standard	O
deviation	O
for	O
the	O
difference	O
of	O
a	O
single	O
experimental	O
treatment	O
–	O
control	O
comparison	O
and	O
makes	O
the	O
results	O
invariant	O
to	O
sample	O
size	O
7	O
.	O

Figure	O
1	O
shows	O
the	O
MSE	O
when	O
the	O
number	O
of	O
experimental	O
treatments	O
K	O
=	O
2	O
and	O
μ	O
0	O
=	O
0	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
05	O
.	O

We	O
assume	O
there	O
is	O
no	O
early	O
stopping	O
for	O
futility	O
,	O
which	O
corresponds	O
to	O
the	O
futility	O
boundary	O
b	O
=−	O
∞.	O

Note	O
that	O
we	O
do	O
not	O
give	O
a	O
plot	O
of	O
the	O
bias	O
because	O
(	O
as	O
expected	O
)	O
the	O
bias	O
of	O
our	O
UMVCUE	O
(	O
as	O
well	O
as	O
the	O
Kimani	O
estimator	O
)	O
is	O
not	O
noticeably	O
different	O
from	O
zero	O
in	O
the	O
simulations	O
.	O

The	O
MSE	O
of	O
the	O
Kimani	O
estimator	O
and	O
UMVCUE	O
are	O
approximately	O
equal	O
,	O
but	O
for	O
all	O
values	O
of	O
t	O
,	O
the	O
UMVCUE	O
has	O
a	O
higher	O
MSE	O
.	O

This	O
difference	O
is	O
an	O
increasing	O
function	O
of	O
t	O
.	O

MSE	O
for	O
various	O
estimators	O
,	O
in	O
units	O
of	O
standard	O
error	O
(	O
SE	O
).	O

We	O
set	O
μ	O
0	O
=	O
0	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
05	O
and	O
b	O
=−	O
∞.	O

There	O
were	O
20000	O
simulated	O
trials	O
for	O
each	O
value	O
of	O
the	O
selection	O
time	O
t	O
.	O

MSE	O
,	O
mean	O
squared	O
error	O
;	O
UMVCUE	O
,	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
.	O

Table	O
1	O
shows	O
the	O
bias	O
and	O
MSE	O
(	O
in	O
units	O
of	O
SE	O
)	O
for	O
a	O
range	O
of	O
representative	O
parameter	O
values	O
,	O
with	O
the	O
selection	O
time	O
t	O
=	O
0	O
.	O
5	O
.	O

As	O
expected	O
,	O
the	O
UMVCUE	O
is	O
unbiased	O
in	O
its	O
mean	O
in	O
all	O
cases	O
.	O

The	O
UMVCUE	O
still	O
has	O
a	O
slightly	O
higher	O
MSE	O
–	O
although	O
it	O
is	O
within	O
10	O
%	O
of	O
the	O
MSE	O
for	O
the	O
Kimani	O
estimator	O
.	O

This	O
difference	O
is	O
a	O
decreasing	O
function	O
of	O
the	O
futility	O
boundary	O
b	O
(	O
or	O
equivalently	O
,	O
an	O
increasing	O
function	O
of	O
the	O
probability	O
of	O
early	O
stopping	O
for	O
futility	O
).	O

Simulation	O
results	O
for	O
t	O
=	O
0	O
.	O
5	O
.	O

There	O
were	O
100000	O
simulations	O
for	O
each	O
set	O
of	O
parameter	O
values	O
.	O

Bias	O
MSE	O
in	O
units	O
of	O
SE	O

Parameter	O
values	O

Naïve	O

Stage	O
2	O

Kimani	O

UMVCUE	O

μ	O
0	O
=	O
0	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
05	O

0	O
.	O
286	O

0	O
.	O
002	O

0	O
.	O
003	O

0	O
.	O
003	O

b	O
=−	O
∞	O

(	O
1	O
.	O
002	O
)	O

(	O
1	O
.	O
412	O
)	O

(	O
1	O
.	O
085	O
)	O

(	O
1	O
.	O
119	O
)	O

μ	O
0	O
=	O
0	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
05	O

0	O
.	O
511	O

−	O
0	O
.	O
008	O

−	O
0	O
.	O
003	O

−	O
0	O
.	O
004	O

b	O
=	O
0	O

(	O
1	O
.	O
002	O
)	O

(	O
1	O
.	O
407	O
)	O

(	O
1	O
.	O
188	O
)	O

(	O
1	O
.	O
198	O
)	O

μ	O
0	O
=	O
0	O
.	O
1	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
3	O

0	O
.	O
276	O

−	O
0	O
.	O
005	O

−	O
0	O
.	O
007	O

−	O
0	O
.	O
006	O

b	O
=−	O
∞	O

(	O
0	O
.	O
997	O
)	O

(	O
1	O
.	O
419	O
)	O

(	O
1	O
.	O
083	O
)	O

(	O
1	O
.	O
119	O
)	O

μ	O
0	O
=	O
0	O
.	O
1	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
3	O

0	O
.	O
330	O

0	O
.	O
004	O

0	O
.	O
004	O

0	O
.	O
005	O

b	O
=	O
0	O
.	O
1	O

(	O
0	O
.	O
986	O
)	O

(	O
1	O
.	O
413	O
)	O

(	O
1	O
.	O
111	O
)	O

(	O
1	O
.	O
140	O
)	O

μ	O
0	O
=	O
0	O
.	O
05	O
,	O
μ	O
1	O
=	O
0	O
.	O
15	O
,	O
μ	O
2	O
=	O
0	O
.	O
1	O

0	O
.	O
439	O

−	O
0	O
.	O
004	O

−	O
0	O
.	O
003	O

−	O
0	O
.	O
004	O

b	O
=	O
0	O

(	O
0	O
.	O
985	O
)	O

(	O
1	O
.	O
414	O
)	O

(	O
1	O
.	O
166	O
)	O

(	O
1	O
.	O
181	O
)	O

μ	O
0	O
=	O
0	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
μ	O
3	O
=	O
μ	O
4	O
=	O
0	O
.	O
05	O

0	O
.	O
650	O

0	O
.	O
005	O

0	O
.	O
005	O

0	O
.	O
003	O

b	O
=	O
0	O
.	O
05	O

(	O
1	O
.	O
087	O
)	O

(	O
1	O
.	O
412	O
)	O

(	O
1	O
.	O
186	O
)	O

(	O
1	O
.	O
222	O
)	O

MSE	O
,	O
mean	O
squared	O
error	O
;	O
UMVCUE	O
,	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
.	O

How	O
can	O
the	O
UMVCUE	O
be	O
worse	O
in	O
terms	O
of	O
MSE	O
?	O

The	O
result	O
that	O
the	O
UMVCUE	O
has	O
a	O
higher	O
MSE	O
than	O
the	O
Kimani	O
estimator	O
seems	O
somewhat	O
counter	O
‐	O
intuitive	O
and	O
indeed	O
seemingly	O
in	O
contradiction	O
of	O
the	O
very	O
definition	O
of	O
the	O
UMVCUE	O
we	O
have	O
derived	O
.	O

However	O
,	O
the	O
explanation	O
is	O
that	O
the	O
two	O
estimators	O
are	O
using	O
different	O
amounts	O
of	O
data	O
.	O

The	O
Kimani	O
estimator	O
is	O
a	O
function	O
of	O
the	O
individual	O
treatment	O
mean	O
outcome	O
statistics	O
X	O
0	O
,	O
X	O
1	O
,…,	O
X	O
K	O
,	O
Y	O
0	O
,	O
Y	O
1	O
,	O
whereas	O
our	O
UMVCUE	O
is	O
a	O
function	O
of	O
X	O
1	O
−	O
X	O
0	O
,…,	O
X	O
K	O
−	O
X	O
0	O
,	O
Y	O
1	O
−	O
Y	O
0	O
.	O

That	O
is	O
,	O
we	O
are	O
not	O
explicitly	O
using	O
the	O
control	O
data	O
X	O
0	O
,	O
Y	O
0	O
in	O
the	O
UMVCUE	O
–	O
all	O
we	O
need	O
are	O
the	O
treatment	O
differences	O
in	O
both	O
stages	O
.	O

In	O
the	O
special	O
case	O
of	O
equal	O
variances	O
,	O
for	O
which	O
the	O
experimental	O
and	O
control	O
group	O
data	O
can	O
be	O
separated	O
,	O
this	O
loss	O
of	O
information	O
results	O
in	O
a	O
slightly	O
greater	O
MSE	O
for	O
the	O
UMVCUE	O
.	O

We	O
return	O
to	O
this	O
issue	O
in	O
the	O
discussion	O
.	O

Unequal	O
variances	O

We	O
have	O
seen	O
that	O
the	O
Kimani	O
estimator	O
performs	O
well	O
when	O
the	O
stages	O
1	O
and	O
2	O
variances	O
are	O
equal	O
.	O

We	O
now	O
explore	O
what	O
happens	O
when	O
this	O
assumption	O
no	O
longer	O
holds	O
–	O
that	O
is	O
,	O
when	O
the	O
σ	O
1i	O
and	O
σ	O
2i	O
are	O
distinct	O
.	O

In	O
this	O
setting	O
,	O
ranking	O
by	O
standardised	O
treatment	O
difference	O
no	O
longer	O
reduces	O
down	O
to	O
ranking	O
by	O
the	O
stage	O
1	O
sample	O
mean	O
.	O

This	O
means	O
that	O
the	O
selection	O
based	O
on	O
standardised	O
observed	O
differences	O
will	O
not	O
necessarily	O
select	O
the	O
treatment	O
with	O
the	O
highest	O
stage	O
1	O
sample	O
mean	O
.	O

The	O
Kimani	O
estimator	O
will	O
overcorrect	O
for	O
bias	O
in	O
this	O
setting	O
,	O
because	O
it	O
assumes	O
that	O
we	O
are	O
always	O
selecting	O
the	O
treatment	O
with	O
the	O
highest	O
treatment	O
effect	O
.	O

We	O
now	O
conduct	O
simulation	O
studies	O
to	O
see	O
to	O
what	O
extent	O
the	O
Kimani	O
estimator	O
is	O
appropriate	O
for	O
the	O
selection	O
rule	O
that	O
uses	O
standardised	O
treatment	O
differences	O
.	O

Although	O
the	O
Kimani	O
estimator	O
is	O
being	O
incorrectly	O
applied	O
in	O
this	O
setting	O
,	O
because	O
it	O
slightly	O
outperformed	O
the	O
UMVCUE	O
in	O
terms	O
of	O
MSE	O
when	O
the	O
variances	O
are	O
equal	O
,	O
it	O
is	O
interesting	O
to	O
investigate	O
whether	O
it	O
does	O
so	O
again	O
.	O

We	O
can	O
straightforwardly	O
modify	O
the	O
Kimani	O
estimator	O
to	O
take	O
into	O
account	O
the	O
differing	O
variances	O
in	O
stages	O
1	O
and	O
2	O
as	O
follows	O
:	O
D1	O
,	O
CHN	O
=	O
Z1	O
,	O
CHN	O
−	O
Z0	O
,	O
CHN	O
=	O
σ212X1	O
+	O
σ112Y1σ112	O
+	O
σ212	O
−	O
σ212σ112	O
+	O
σ212ϕ	O
(	O
WB	O
)	O
Φ	O
(	O
WB	O
)−	O
σ202X0	O
+	O
σ102Y0σ102	O
+	O
σ202	O
+	O
σ202σ102	O
+	O
σ202ϕWB1ΦWB1	O
,	O
where	O
WB	O
=	O
σ112	O
+	O
σ212σ112σ212X1	O
+	O
σ112Y1σ112	O
+	O
σ212	O
−	O
maxX0	O
+	O
bσ112	O
+	O
σ102	O
,	O
X2WB1	O
=	O
σ102	O
+	O
σ202σ102X1	O
−	O
bσ112	O
+	O
σ102	O
−	O
σ202X0	O
+	O
σ102Y0σ102	O
+	O
σ202	O
.	O
Consider	O
now	O
the	O
scenario	O
where	O
K	O
=	O
2	O
and	O
one	O
of	O
the	O
experimental	O
treatments	O
has	O
variance	O
σ	O
~	O
12	O
say	O
,	O
whereas	O
the	O
other	O
experimental	O
treatment	O
and	O
the	O
control	O
both	O
have	O
variance	O
equal	O
to	O
1	O
.	O

Figure	O
2	O
shows	O
the	O
(	O
unadjusted	O
)	O
bias	O
and	O
MSE	O
for	O
the	O
various	O
estimators	O
where	O
we	O
vary	O
σ	O
~	O
1	O
from	O
0	O
.	O
25	O
to	O
4	O
.	O

We	O
also	O
set	O
σ	O
21	O
=	O
σ	O
11	O
,	O
whilst	O
keeping	O
σ	O
20	O
=	O
1	O
.	O

Note	O
that	O
σ112	O
is	O
the	O
variance	O
of	O
the	O
treatment	O
that	O
is	O
selected	O
to	O
continue	O
to	O
stage	O
2	O
.	O

Bias	O
and	O
MSE	O
for	O
the	O
estimators	O
,	O
using	O
individual	O
variances	O
for	O
the	O
Kimani	O
estimator	O
.	O

We	O
set	O
μ	O
0	O
=	O
0	O
,	O
μ	O
1	O
=	O
μ	O
2	O
=	O
0	O
.	O
05	O
,	O
σ	O
21	O
=	O
σ	O
11	O
and	O
σ	O
10	O
=	O
σ	O
20	O
=	O
1	O
.	O

There	O
were	O
50000	O
simulated	O
trials	O
for	O
each	O
value	O
of	O
σ	O
~	O
1	O
.	O

If	O
we	O
assume	O
a	O
common	O
variance	O
σ	O
2	O
across	O
treatment	O
groups	O
,	O
then	O
values	O
of	O
σ	O
~	O
1	O
>	O
2	O
(	O
or	O
<	O
0	O
.	O
5	O
)	O
imply	O
unrealistic	O
unequal	O
allocations	O
to	O
the	O
treatment	O
groups	O
that	O
would	O
rarely	O
occur	O
in	O
practice	O
.	O

However	O
,	O
such	O
scenarios	O
could	O
occur	O
where	O
there	O
is	O
reason	O
to	O
believe	O
treatment	O
1	O
has	O
a	O
different	O
treatment	O
effect	O
variance	O
from	O
the	O
other	O
treatment	O
(	O
and	O
the	O
control	O
)	O
after	O
looking	O
at	O
previous	O
trial	O
or	O
pilot	O
study	O
data	O
.	O

This	O
may	O
make	O
biological	O
sense	O
too	O
,	O
if	O
treatment	O
1	O
is	O
a	O
different	O
class	O
of	O
drug	O
to	O
the	O
others	O
.	O

In	O
that	O
case	O
,	O
we	O
could	O
have	O
σ	O
~	O
1	O
>	O
2	O
despite	O
having	O
equal	O
allocation	O
ratios	O
to	O
the	O
treatment	O
groups	O
and	O
the	O
control	O
.	O

As	O
expected	O
,	O
the	O
stage	O
2	O
estimator	O
and	O
UMVCUE	O
are	O
unbiased	O
for	O
all	O
values	O
of	O
σ	O
~	O
1	O
,	O
whilst	O
the	O
naïve	O
estimator	O
is	O
positively	O
biased	O
.	O

However	O
,	O
we	O
see	O
that	O
for	O
σ	O
~	O
1	O
≠	O
1	O
,	O
the	O
Kimani	O
estimator	O
is	O
negatively	O
biased	O
,	O
with	O
the	O
bias	O
much	O
worse	O
when	O
b	O
=−	O
∞	O
compared	O
with	O
b	O
=	O
0	O
.	O
1	O
.	O

This	O
negative	O
bias	O
steadily	O
increases	O
as	O
σ	O
~	O
1	O
increases	O
above	O
1	O
.	O

Indeed	O
,	O
when	O
σ	O
~	O
1	O
=	O
4	O
,	O
the	O
Kimani	O
estimator	O
has	O
a	O
substantial	O
bias	O
when	O
b	O
=−	O
∞(	O
which	O
corresponds	O
to	O
an	O
early	O
stopping	O
probability	O
of	O
0	O
).	O

In	O
terms	O
of	O
the	O
MSE	O
,	O
as	O
expected	O
the	O
naïve	O
estimator	O
has	O
the	O
lowest	O
MSE	O
.	O

The	O
Kimani	O
estimator	O
has	O
a	O
higher	O
MSE	O
than	O
the	O
UMVCUE	O
except	O
when	O
σ	O
~	O
1	O
is	O
close	O
to	O
1	O
.	O

There	O
is	O
a	O
steady	O
increase	O
in	O
the	O
Kimani	O
estimator	O
'	O
s	O
MSE	O
for	O
σ	O
~	O
1	O
>	O
1	O
.	O

The	O
MSE	O
of	O
the	O
UMVCUE	O
is	O
slightly	O
higher	O
when	O
b	O
=	O
0	O
.	O
1	O
compared	O
with	O
b	O
=−	O
∞	O
and	O
vice	O
‐	O
versa	O
for	O
the	O
MSE	O
of	O
the	O
Kimani	O
estimator	O
.	O

Unbiased	O
estimation	O
for	O
hypothesis	O
‐	O
driven	O
designs	O

Finally	O
,	O
we	O
look	O
at	O
the	O
application	O
of	O
our	O
estimator	O
within	O
the	O
context	O
of	O
formal	O
hypothesis	O
testing	O
.	O

We	O
illustrate	O
this	O
with	O
an	O
example	O
based	O
on	O
the	O
case	O
study	O
in	O
16	O
.	O

Suppose	O
we	O
are	O
comparing	O
three	O
experimental	O
drugs	O
with	O
a	O
placebo	O
for	O
the	O
treatment	O
of	O
generalised	B-DS
anxiety	I-DS
disorder	I-DS
.	O

We	O
assume	O
that	O
the	O
outcomes	O
(	O
the	O
total	O
score	O
on	O
the	O
Hamilton	O
Rating	O
Scale	O
for	O
Anxiety	B-DS
)	O
are	O
normally	O
distributed	O
with	O
common	O
standard	O
deviation	O
σ	O
=	O
6	O
.	O

The	O
trial	O
is	O
planned	O
with	O
equal	O
allocations	O
to	O
each	O
treatment	O
,	O
with	O
n	O
1	O
=	O
n	O
2	O
=	O
71	O
subjects	O
per	O
group	O
.	O

However	O
,	O
suppose	O
that	O
the	O
randomisation	O
procedure	O
used	O
leads	O
to	O
an	O
unequal	O
number	O
of	O
subjects	O
in	O
each	O
treatment	O
group	O
.	O

Table	O
2	O
shows	O
the	O
observed	O
data	O
for	O
both	O
stages	O
of	O
the	O
trial	O
.	O

Example	O
data	O
from	O
a	O
seamless	O
phase	O
II	O
/	O
III	O
trial	O
.	O

Stage	O
1	O

Stage	O
2	O

n	O
1i	O

Observed	O

z	O
‐	O
statistic	O

p	O
1i	O

n	O
2i	O

Observed	O

Placebo	O

70	O

0	O
.	O
4	O

—	O

—	O

68	O

−	O
0	O
.	O
3	O

Treatment	O
1	O

72	O

2	O
.	O
2	O

1	O
.	O
787	O

0	O
.	O
0369	O

75	O

1	O
.	O
7	O

Treatment	O
2	O

68	O

2	O
.	O
4	O

1	O
.	O
958	O

0	O
.	O
0251	O

70	O

2	O
.	O
2	O

Treatment	O
3	O

74	O

3	O
.	O
2	O

2	O
.	O
799	O

0	O
.	O
0026	O

71	O

1	O
.	O
9	O

The	O
aim	O
is	O
to	O
take	O
forward	O
as	O
many	O
treatments	O
as	O
possible	O
that	O
pass	O
a	O
first	O
‐	O
stage	O
p	O
‐	O
value	O
futility	O
threshold	O
,	O
set	O
at	O
α	O
0	O
=	O
0	O
.	O
1	O
.	O

As	O
we	O
are	O
in	O
a	O
multiple	O
testing	O
situation	O
,	O
we	O
use	O
multiplicity	O
corrected	O
p	O
‐	O
values	O
and	O
the	O
closure	O
principle	O
in	O
our	O
analysis	O
(	O
see	O
Section	O
4	O
.	O
2	O
).	O

Although	O
the	O
primary	O
focus	O
will	O
be	O
hypothesis	O
testing	O
,	O
estimation	O
of	O
the	O
treatment	O
effects	O
is	O
an	O
important	O
secondary	O
goal	O
,	O
and	O
we	O
would	O
like	O
unbiased	O
estimates	O
of	O
the	O
selected	O
treatments	O
'	O
benefit	O
over	O
control	O
at	O
the	O
end	O
of	O
the	O
trial	O
.	O

This	O
means	O
that	O
we	O
need	O
a	O
way	O
of	O
estimating	O
the	O
treatment	O
difference	O
when	O
(	O
i	O
)	O
multiple	O
treatments	O
are	O
taken	O
forward	O
to	O
stage	O
2	O
,	O
and	O
(	O
ii	O
)	O
the	O
treatments	O
are	O
not	O
ranked	O
using	O
a	O
rule	O
that	O
is	O
concordant	O
with	O
ranking	O
by	O
the	O
stage	O
1	O
sample	O
mean	O
alone	O
.	O

In	O
these	O
cases	O
,	O
the	O
Kimani	O
estimator	O
cannot	O
be	O
used	O
,	O
and	O
hence	O
we	O
need	O
to	O
extend	O
our	O
methodology	O
(	O
see	O
succeeding	O
text	O
).	O

Uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
for	O
the	O
jth	O
‐	O
ranked	O
treatment	O

Suppose	O
that	O
we	O
take	O
forward	O
the	O
top	O
K	O
treatments	O
from	O
a	O
larger	O
group	O
of	O
K	O
′.	O

We	O
want	O
to	O
find	O
the	O
UMVCUE	O
for	O
the	O
jth	O
best	O
treatment	O
out	O
of	O
K	O
.	O

Let	O
T	O
j	O
=	O
Y	O
j	O
−	O
Y	O
0	O
denote	O
the	O
stage	O
2	O
sample	O
mean	O
treatment	O
differences	O
for	O
j	O
∈{	O
1	O
,…,	O
K	O
}.	O

We	O
consider	O
the	O
more	O
general	O
early	O
stopping	O
rules	O
where	O
the	O
jth	O
‐	O
ranked	O
treatment	O
proceeds	O
to	O
stage	O
2	O
if	O
λ	O
j	O
(	O
X	O
j	O
−	O
X	O
0	O
)	O
>	O
b	O
j	O
.	O

For	O
notational	O
convenience	O
,	O
let	O
νj2	O
=	O
σ102	O
+	O
σ1j2	O
and	O
τj2	O
=	O
σ202	O
+	O
σ2j2	O
.	O

Then	O
from	O
the	O
multivariate	O
normal	O
theory	O
15	O
,	O
for	O
a	O
given	O
value	O
of	O
j	O
∈{	O
1	O
,…,	O
K	O
}	O
the	O
statistic	O
Zj	O
=	O
(	O
Z	O
1j	O
,…,	O
Z	O
Kj	O
)	O
is	O
sufficient	O
and	O
complete	O
for	O
θ	O
,	O
where	O
Zjj	O
=	O
Θj	O
+	O
νj2τj2TjZij	O
=	O
Θi	O
+	O
σ102τj2Tji	O
≠	O
j	O
,	O
i	O
∈{	O
1	O
,…,	O
K	O
}.	O
This	O
time	O
,	O
we	O
are	O
conditioning	O
on	O
the	O
modified	O
event	O
Q	O
′,	O
where	O
Q	O
′={	O
Θ	O
:	O
λ	O
1Θ1	O
>⋯>	O
λ	O
KΘK	O
,	O
λ	O
1Θ1	O
>	O
b	O
1	O
,…,	O
λ	O
KΘK	O
>	O
b	O
K	O
}.	O

Then	O
the	O
UMVCUE	O
for	O
the	O
jth	O
‐	O
ranked	O
treatment	O
(	O
denoted	O
Ûj	O
)	O
is	O
shown	O
in	O
Theorem	O
4	O
.	O
1	O
with	O
a	O
proof	O
provided	O
in	O
Appendix	O
A	O
.	O
2	O
.	O
Theorem	O
4	O
.	O
1For	O
a	O
given	O
value	O
of	O
j	O
∈{	O
1	O
,…,	O
K	O
},	O
the	O
UMVCUE	O
for	O
θ	O
j	O
=	O
μ	O
j	O
−	O
μ	O
0	O
given	O
Q	O
′	O
is	O
(	O
6	O
)	O
Ûj	O
=	O
τj2Zjjνj2	O
+	O
τj2	O
−	O
τj2νj2	O
+	O
τj2ϕ	O
(	O
W1	O
)−	O
ϕ	O
(	O
W2	O
)	O
Φ	O
(	O
W1	O
)−	O
Φ	O
(	O
W2	O
),	O
where	O
Wi	O
=	O
kiνj2	O
+	O
τj2τj2	O
−	O
Zjjνj2	O
+	O
τj2fori	O
=	O
1	O
,	O
2	O
;	O
k1	O
=	O
min	O
(	O
A1	O
,	O
A2	O
,	O
A3	O
,	O
A4	O
,	O
A5	O
),	O
k2	O
=	O
max	O
(	O
A6	O
,	O
A7	O
,	O
A8	O
),	O
A1	O
=	O
τj2νj2Zjj	O
−	O
bjλj	O
;	O
A2	O
=	O
τj2σ102Zij	O
−	O
biλi	O
:	O
i	O
≠	O
j	O
,	O
i	O
∈{	O
1	O
,…,	O
K	O
},	O
A3	O
=	O
τj2λjZjj	O
−	O
λj	O
+	O
1Zj	O
+	O
1	O
,	O
jσ102λj	O
−	O
λj	O
+	O
1	O
+	O
λjσ1j2	O
:	O
λjσ1j2	O
>	O
λj	O
+	O
1	O
−	O
λjσ102	O
;	O
j	O
≠	O
K	O
,	O
A4	O
=	O
τj2λjZjj	O
−	O
λj	O
−	O
1Zj	O
−	O
1	O
,	O
jσ102λj	O
−	O
λj	O
−	O
1	O
+	O
λjσ1j2	O
:	O
λjσ1j2	O
<	O
λj	O
−	O
1	O
−	O
λjσ102	O
;	O
j	O
≠	O
1	O
,	O
A5	O
=	O
τ2λiZij	O
−	O
λi	O
+	O
1Zi	O
+	O
1	O
,	O
jσ102λi	O
−	O
λi	O
+	O
1	O
:	O
σ1	O
,	O
i	O
+	O
12	O
>	O
σ1i2	O
;	O
i	O
∈{	O
1	O
,…,	O
K	O
−	O
1	O
}/{	O
j	O
−	O
1	O
,	O
j	O
},	O
A6	O
=	O
τj2λjZjj	O
−	O
λj	O
+	O
1Zj	O
+	O
1	O
,	O
jσ102	O
(	O
λj	O
−	O
λj	O
+	O
1	O
)+	O
λjσ1j2	O
:	O
λjσ1j2	O
<	O
λj	O
+	O
1	O
−	O
λjσ102	O
;	O
j	O
≠	O
K	O
,	O
A7	O
=	O
τj2λjZjj	O
−	O
λj	O
−	O
1Zj	O
−	O
1	O
,	O
jσ102λj	O
−	O
λj	O
−	O
1	O
+	O
λjσ1j2	O
:	O
λjσ1j2	O
>	O
λj	O
−	O
1	O
−	O
λjσ102	O
;	O
j	O
≠	O
1	O
,	O
A8	O
=	O
τ2λiZij	O
−	O
λi	O
+	O
1Zi	O
+	O
1	O
,	O
jσ102λi	O
−	O
λi	O
+	O
1	O
:	O
σ1	O
,	O
i	O
+	O
12	O
<	O
σ1i2	O
;	O
i	O
∈{	O
1	O
,…,	O
K	O
−	O
1	O
}/{	O
j	O
−	O
1	O
,	O
j	O
},	O
and	O
we	O
define	O
min	O
({∅})	O
=+	O
∞	O
and	O
max	O
({∅})	O
=−	O
∞.	O

Uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
with	O
the	O
closure	O
principle	O

We	O
can	O
now	O
start	O
to	O
apply	O
our	O
UMVCUE	O
to	O
the	O
example	O
trial	O
setting	O
.	O

In	O
general	O
,	O
assume	O
that	O
we	O
are	O
testing	O
the	O
K	O
directional	O
null	O
hypotheses	O
Hi	O
:	O
μi	O
≤	O
μ0	O
(	O
i	O
=	O
1	O
,…,	O
K	O
)	O
comparing	O
the	O
K	O
treatments	O
with	O
the	O
control	O
.	O

Our	O
aim	O
is	O
to	O
strongly	O
control	O
the	O
familywise	O
error	O
rate	O
(	O
FWER	O
)	O
at	O
a	O
pre	O
‐	O
specified	O
level	O
α	O
,	O
where	O
strong	O
FWER	O
is	O
defined	O
as	O
the	O
(	O
maximum	O
)	O
probability	O
of	O
rejecting	O
at	O
least	O
one	O
true	O
null	O
hypothesis	O
,	O
irrespective	O
of	O
the	O
configuration	O
of	O
true	O
and	O
false	O
null	O
hypotheses	O
17	O
.	O

To	O
control	O
the	O
FWER	O
,	O
we	O
use	O
the	O
closure	O
principle	O
(	O
CP	O
)	O
18	O
.	O

The	O
CP	O
considers	O
all	O
intersection	O
hypotheses	O
that	O
are	O
constructed	O
from	O
the	O
elementary	O
null	O
hypotheses	O
.	O

To	O
strongly	O
control	O
the	O
FWER	O
,	O
an	O
elementary	O
null	O
hypothesis	O
H	O
i	O
can	O
only	O
be	O
rejected	O
if	O
all	O
intersection	O
hypotheses	O
implying	O
H	O
i	O
are	O
rejected	O
also	O
.	O

For	O
more	O
details	O
,	O
we	O
refer	O
the	O
reader	O
to	O
the	O
papers	O
of	O
Bretz	O
et	O
al	O
.	O
13	O
,	O
16	O
.	O

In	O
order	O
to	O
test	O
an	O
intersection	O
hypothesis	O
at	O
the	O
end	O
of	O
a	O
two	O
‐	O
stage	O
trial	O
,	O
we	O
begin	O
by	O
correcting	O
for	O
multiplicity	O
for	O
each	O
stage	O
separately	O
.	O

Only	O
afterwards	O
do	O
we	O
combine	O
the	O
resulting	O
adjusted	O
p	O
‐	O
values	O
into	O
a	O
pre	O
‐	O
specified	O
combination	O
function	O
C	O
(	O
p	O
,	O
q	O
).	O

Given	O
an	O
intersection	O
hypothesis	O
H	O
I	O
(	O
where	O
I	O
⊆{	O
1	O
,…,	O
K	O
})	O
and	O
the	O
corresponding	O
multiplicity	O
‐	O
adjusted	O
stage	O
1	O
p	O
‐	O
value	O
p	O
1I	O
and	O
stage	O
2	O
p	O
‐	O
value	O
p	O
2I	O
,	O
we	O
reject	O
H	O
I	O
in	O
the	O
final	O
analysis	O
if	O
C	O
(	O
p1I	O
,	O
p2I	O
)≤	O
c	O
(	O
where	O
c	O
is	O
a	O
suitably	O
chosen	O
critical	O
value	O
to	O
ensure	O
a	O
pre	O
‐	O
specified	O
type	O
I	O
error	O
rate	O
of	O
α	O
).	O

As	O
an	O
example	O
,	O
consider	O
using	O
the	O
closed	O
testing	O
procedure	O
for	O
the	O
stage	O
1	O
data	O
with	O
early	O
stopping	O
for	O
futility	O
,	O
using	O
the	O
Bonferonni	O
correction	O
for	O
multiplicity	O
(	O
for	O
the	O
sake	O
of	O
simplicity	O
).	O

The	O
usual	O
first	O
‐	O
stage	O
(	O
unadjusted	O
)	O
p	O
‐	O
values	O
for	O
treatment	O
i	O
∈{	O
1	O
,…,	O
K	O
},	O
denoted	O
p	O
1	O
,	O
i	O
,	O
are	O
as	O
follows	O
:	O
p1	O
,	O
i	O
=	O
1	O
−	O
ΦXi	O
−	O
X0σ1i2	O
+	O
σ102	O
.	O
For	O
notational	O
convenience	O
,	O
let	O
r	O
(	O
Xi	O
)=	O
Xi	O
−	O
X0σ1i2	O
+	O
σ102	O
denote	O
the	O
standardised	O
treatment	O
difference	O
for	O
treatment	O
i	O
∈{	O
1	O
,…,	O
K	O
}.	O

Consider	O
comparing	O
K	O
=	O
3	O
treatments	O
with	O
a	O
control	O
(	O
as	O
in	O
our	O
example	O
),	O
as	O
shown	O
in	O
Figure	O
3	O
.	O

Closed	O
testing	O
procedure	O
for	O
the	O
stage	O
1	O
data	O
using	O
the	O
Bonferonni	O
correction	O
,	O
with	O
K	O
=	O
3	O
treatments	O
.	O

By	O
the	O
CP	O
,	O
treatment	O
1	O
(	O
say	O
)	O
continues	O
to	O
stage	O
2	O
if	O
p1	O
,{	O
1	O
,	O
2	O
,	O
3	O
}<	O
α0	O
⇒	O
maxi	O
∈{	O
1	O
,	O
2	O
,	O
3	O
}	O
r	O
(	O
Xi	O
)>	O
Φ	O
−	O
11	O
−	O
α0	O
/	O
3p1	O
,{	O
1	O
,	O
2	O
}<	O
α0	O
⇒	O
maxi	O
∈{	O
1	O
,	O
2	O
}	O
r	O
(	O
Xi	O
)>	O
Φ	O
−	O
11	O
−	O
α0	O
/	O
2p1	O
,{	O
1	O
,	O
3	O
}<	O
α0	O
⇒	O
maxi	O
∈{	O
1	O
,	O
3	O
}	O
r	O
(	O
Xi	O
)>	O
Φ	O
−	O
11	O
−	O
α0	O
/	O
2p1	O
,	O
1	O
<	O
α0	O
⇒	O
r	O
(	O
X1	O
)>	O
Φ	O
−	O
11	O
−	O
α0	O
.	O
Without	O
loss	O
of	O
generality	O
,	O
suppose	O
r	O
(	O
X	O
1	O
)	O
>	O
r	O
(	O
X	O
2	O
)	O
>	O
r	O
(	O
X	O
3	O
).	O

Then	O
maxi	O
∈{	O
1	O
,	O
2	O
,	O
3	O
}	O
r	O
(	O
X	O
i	O
)	O
=	O
r	O
(	O
X	O
1	O
),	O
and	O
treatment	O
1	O
continues	O
to	O
stage	O
2	O
if	O
r	O
(	O
X	O
1	O
)	O
>	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
3	O
).	O

Hence	O
,	O
conditional	O
on	O
the	O
event	O
Q	O
={	O
X	O
:	O
r	O
(	O
X	O
1	O
)	O
>	O
r	O
(	O
X	O
2	O
)	O
>	O
r	O
(	O
X	O
3	O
),	O
r	O
(	O
X	O
1	O
)	O
>	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
3	O
)},	O
the	O
UMVCUE	O
for	O
θ	O
1	O
=	O
μ	O
1	O
−	O
μ	O
0	O
is	O
given	O
by	O
Equation	O
(	O
3	O
),	O
where	O
K	O
=	O
3	O
and	O
b	O
=	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
3	O
).	O

If	O
treatment	O
2	O
also	O
continues	O
to	O
stage	O
2	O
,	O
then	O
the	O
UMVCUE	O
for	O
θ	O
2	O
=	O
μ	O
2	O
−	O
μ	O
0	O
is	O
given	O
by	O
Equation	O
(	O
6	O
),	O
where	O
we	O
set	O
K	O
=	O
3	O
,	O
b	O
1	O
=	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
3	O
),	O
b	O
2	O
=	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
2	O
)	O
and	O
b	O
3	O
=−∞.	O

Finally	O
,	O
if	O
treatment	O
3	O
continues	O
to	O
stage	O
2	O
,	O
then	O
the	O
UMVCUE	O
for	O
θ	O
3	O
=	O
μ	O
3	O
−	O
μ	O
0	O
is	O
given	O
by	O
Equation	O
(	O
6	O
),	O
with	O
K	O
=	O
3	O
,	O
b	O
1	O
=	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
3	O
),	O
b	O
2	O
=	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
/	O
2	O
)	O
and	O
b	O
3	O
=	O
Φ	O
−	O
1	O
(	O
1	O
−	O
α	O
0	O
).	O

Example	O
analysis	O

Returning	O
to	O
the	O
data	O
from	O
our	O
example	O
trial	O
,	O
we	O
can	O
calculate	O
the	O
stage	O
1	O
Bonferroni	O
‐	O
adjusted	O
p	O
‐	O
values	O
as	O
given	O
as	O
follows	O
:	O
p1	O
,{	O
1	O
,	O
2	O
,	O
3	O
}=	O
0	O
.	O
0077p1	O
,{	O
1	O
,	O
2	O
}=	O
0	O
.	O
0503	O
,	O
p1	O
,{	O
1	O
,	O
3	O
}=	O
0	O
.	O
0051	O
,	O
p1	O
,{	O
2	O
,	O
3	O
}=	O
0	O
.	O
0051p1	O
,	O
1	O
=	O
0	O
.	O
0369	O
,	O
p1	O
,	O
2	O
=	O
0	O
.	O
0251	O
,	O
p1	O
,	O
3	O
=	O
0	O
.	O
0026	O
.	O
Because	O
all	O
of	O
the	O
adjusted	O
p	O
‐	O
values	O
are	O
less	O
than	O
α	O
0	O
,	O
the	O
futility	O
boundary	O
threshold	O
is	O
not	O
crossed	O
for	O
any	O
of	O
the	O
doses	O
,	O
and	O
hence	O
,	O
all	O
of	O
the	O
dose	O
groups	O
(	O
and	O
placebo	O
)	O
are	O
continued	O
to	O
stage	O
2	O
.	O

Plugging	O
in	O
the	O
observed	O
values	O
(	O
and	O
known	O
variances	O
),	O
the	O
naïve	O
estimator	O
,	O
stage	O
2	O
estimator	O
and	O
UMVCUE	O
for	O
the	O
differences	O
between	O
the	O
doses	O
are	O
given	O
in	O
Table	O
3	O
.	O

We	O
see	O
that	O
the	O
UMVCUE	O
can	O
be	O
higher	O
or	O
lower	O
than	O
both	O
the	O
naïve	O
and	O
stage	O
2	O
estimators	O
and	O
is	O
not	O
necessarily	O
closer	O
to	O
the	O
stage	O
2	O
data	O
.	O

Estimators	O
for	O
the	O
treatment	O
differences	O
from	O
a	O
seamless	O
phase	O
II	O
/	O
III	O
trial	O
.	O

Stage	O
1	O
Rank	O

Treatment	O

Naïve	O

Stage	O
2	O

UMVCUE	O

1	O

3	O

2	O
.	O
505	O

2	O
.	O
200	O

2	O
.	O
285	O

2	O

2	O

2	O
.	O
250	O

2	O
.	O
500	O

2	O
.	O
020	O

3	O

1	O

1	O
.	O
900	O

2	O
.	O
000	O

2	O
.	O
062	O

UMVCUE	O
,	O
uniformly	O
minimum	O
variance	O
conditionally	O
unbiased	O
estimator	O
.	O

As	O
a	O
brief	O
comparison	O
,	O
the	O
Kimani	O
estimator	O
for	O
the	O
highest	O
ranked	O
treatment	O
is	O
2	O
.	O
197	O
using	O
the	O
modified	O
formula	O
shown	O
in	O
Section	O
3	O
.	O
2	O
.	O

Both	O
these	O
values	O
are	O
lower	O
than	O
the	O
the	O
UMVCUE	O
and	O
the	O
stage	O
2	O
estimator	O
,	O
which	O
may	O
be	O
a	O
reflection	O
of	O
the	O
fact	O
that	O
Kimani	O
estimator	O
overcorrects	O
for	O
bias	O
.	O

Note	O
that	O
the	O
Kimani	O
estimator	O
is	O
only	O
for	O
the	O
highest	O
ranked	O
treatment	O
,	O
and	O
estimates	O
for	O
the	O
other	O
treatment	O
differences	O
are	O
unavailable	O
.	O

Finally	O
,	O
if	O
we	O
want	O
to	O
test	O
the	O
elementary	O
hypotheses	O
H	O
1	O
,	O
H	O
2	O
and	O
H	O
3	O
at	O
the	O
end	O
of	O
the	O
trial	O
,	O
we	O
first	O
need	O
to	O
find	O
the	O
stage	O
2	O
Bonferroni	O
‐	O
adjusted	O
p	O
‐	O
values	O
:	O
p2	O
,{	O
1	O
,	O
2	O
,	O
3	O
}=	O
0	O
.	O
0216p2	O
,{	O
1	O
,	O
2	O
}=	O
0	O
.	O
0144	O
,	O
p2	O
,{	O
1	O
,	O
3	O
}=	O
0	O
.	O
0307	O
,	O
p2	O
,{	O
2	O
,	O
3	O
}=	O
0	O
.	O
0144p2	O
,	O
1	O
=	O
0	O
.	O
0233	O
,	O
p2	O
,	O
2	O
=	O
0	O
.	O
0072	O
,	O
p2	O
,	O
3	O
=	O
0	O
.	O
0153	O
.	O
In	O
order	O
to	O
combine	O
the	O
adjusted	O
p	O
‐	O
values	O
,	O
we	O
use	O
the	O
well	O
‐	O
known	O
weighted	O
inverse	O
normal	O
combination	O
function	O
C	O
(	O
p	O
,	O
q	O
)	O
=	O
1	O
−	O
Φ	O
[	O
w	O
1	O
Φ	O
−	O
1	O
(	O
1	O
−	O
p	O
)	O
+	O
w	O
2	O
Φ	O
−	O
1	O
(	O
1	O
−	O
q	O
)],	O
where	O
the	O
weights	O
w	O
1	O
,	O
w	O
2	O
are	O
set	O
proportional	O
to	O
the	O
originally	O
planned	O
stage	O
‐	O
wise	O
sample	O
sizes	O
:	O
w1	O
=	O
w2	O
=	O
1	O
/	O
2	O
.	O

Because	O
α	O
0	O
=	O
0	O
.	O
1	O
,	O
then	O
setting	O
α	O
=	O
0	O
.	O
025	O
means	O
that	O
the	O
critical	O
value	O
c	O
=	O
0	O
.	O
0401	O
.	O

Taking	O
dose	O
level	O
3	O
as	O
an	O
example	O
,	O
by	O
the	O
CP	O
,	O
to	O
reject	O
H	O
3	O
,	O
we	O
also	O
need	O
to	O
reject	O
the	O
intersection	O
hypotheses	O
H	O
{	O
1	O
,	O
2	O
,	O
3	O
},	O
H	O
{	O
1	O
,	O
3	O
}	O
and	O
H	O
{	O
2	O
,	O
3	O
}.	O

Because	O
C	O
(	O
p	O
1	O
,{	O
1	O
,	O
2	O
,	O
3	O
},	O
p	O
2	O
,{	O
1	O
,	O
2	O
,	O
3	O
})	O
<	O
c	O
,	O
C	O
(	O
p	O
1	O
,{	O
1	O
,	O
3	O
},	O
p	O
2	O
,{	O
1	O
,	O
3	O
})	O
<	O
c	O
,	O
C	O
(	O
p	O
1	O
,{	O
2	O
,	O
3	O
},	O
p	O
2	O
,{	O
2	O
,	O
3	O
})	O
<	O
c	O
and	O
C	O
(	O
p	O
1	O
,	O
3	O
,	O
p	O
2	O
,	O
3	O
)	O
<	O
c	O
,	O
then	O
we	O
can	O
indeed	O
reject	O
H	O
3	O
and	O
conclude	O
that	O
treatment	O
3	O
is	O
superior	O
to	O
placebo	O
.	O

Similarly	O
,	O
following	O
the	O
same	O
procedure	O
,	O
we	O
can	O
also	O
reject	O
H	O
2	O
and	O
H	O
1	O
.	O

Note	O
that	O
unlike	O
hypothesis	O
testing	O
for	O
the	O
closure	O
principle	O
that	O
strongly	O
controls	O
the	O
type	O
I	O
error	O
regardless	O
of	O
the	O
number	O
of	O
treatments	O
that	O
continue	O
to	O
stage	O
2	O
,	O
if	O
the	O
estimates	O
obtained	O
after	O
stage	O
2	O
are	O
used	O
to	O
select	O
the	O
most	O
effective	O
treatment	O
,	O
all	O
the	O
estimators	O
compared	O
in	O
Table	O
3	O
are	O
biased	O
.	O

That	O
is	O
,	O
the	O
estimators	O
derived	O
in	O
this	O
section	O
are	O
only	O
unbiased	O
if	O
the	O
treatments	O
will	O
not	O
be	O
ranked	O
after	O
stage	O
2	O
.	O

This	O
is	O
because	O
the	O
estimators	O
do	O
not	O
adjust	O
for	O
additional	O
selection	O
at	O
the	O
end	O
of	O
the	O
trial	O
.	O

Discussion	O

In	O
seamless	O
phase	O
II	O
/	O
III	O
trials	O
,	O
it	O
may	O
be	O
desirable	O
to	O
explicitly	O
take	O
into	O
account	O
differences	O
in	O
the	O
precision	O
of	O
the	O
treatment	O
effect	O
estimates	O
.	O

Also	O
,	O
if	O
more	O
than	O
one	O
treatment	O
is	O
taken	O
forward	O
to	O
the	O
second	O
stage	O
,	O
then	O
it	O
is	O
natural	O
to	O
estimate	O
the	O
effect	O
of	O
treatments	O
other	O
than	O
the	O
highest	O
ranked	O
.	O

In	O
this	O
paper	O
,	O
we	O
described	O
a	O
framework	O
for	O
unbiased	O
estimation	O
that	O
is	O
applicable	O
in	O
full	O
generality	O
for	O
the	O
jth	O
‐	O
ranked	O
treatment	O
,	O
where	O
the	O
precision	O
of	O
treatment	O
effect	O
estimates	O
can	O
take	O
arbitrary	O
values	O
.	O

Our	O
generalised	O
early	O
stopping	O
rules	O
for	O
futility	O
means	O
that	O
our	O
methodology	O
can	O
be	O
applied	O
where	O
the	O
interim	O
selection	O
rules	O
are	O
driven	O
by	O
formal	O
hypothesis	O
testing	O
procedures	O
,	O
as	O
would	O
be	O
expecting	O
in	O
practice	O
.	O

Our	O
UMVCUE	O
for	O
the	O
maximum	O
treatment	O
difference	O
is	O
different	O
analytically	O
from	O
the	O
Kimani	O
et	O
al	O
.	O
estimator	O
in	O
the	O
special	O
case	O
where	O
the	O
treatment	O
effect	O
variances	O
are	O
equal	O
within	O
each	O
stage	O
.	O

Somewhat	O
counter	O
‐	O
intuitively	O
,	O
our	O
numerical	O
simulations	O
showed	O
that	O
when	O
this	O
special	O
case	O
is	O
satisfied	O
,	O
our	O
UMVCUE	O
is	O
slightly	O
less	O
efficient	O
.	O

The	O
reason	O
is	O
that	O
the	O
Kimani	O
estimator	O
uses	O
all	O
of	O
the	O
data	O
X	O
0	O
,	O
X	O
1	O
,…,	O
X	O
K	O
,	O
Y	O
0	O
,	O
Y	O
1	O
explicitly	O
,	O
whereas	O
the	O
UMVCUE	O
uses	O
only	O
the	O
treatment	O
differences	O
X	O
1	O
−	O
X	O
0	O
,…,	O
X	O
K	O
−	O
X	O
0	O
,	O
Y	O
1	O
−	O
Y	O
0	O
.	O

Hence	O
,	O
if	O
selection	O
is	O
indeed	O
based	O
on	O
the	O
observed	O
stage	O
1	O
sample	O
means	O
,	O
then	O
we	O
would	O
recommend	O
using	O
the	O
Kimani	O
estimator	O
(	O
or	O
its	O
modification	O
when	O
variances	O
in	O
different	O
treatment	O
arms	O
cannot	O
be	O
assumed	O
equal	O
).	O

When	O
we	O
do	O
in	O
fact	O
have	O
unequal	O
variances	O
and	O
rank	O
by	O
standardised	O
treatment	O
difference	O
,	O
then	O
our	O
simulation	O
results	O
demonstrate	O
how	O
the	O
Kimani	O
estimator	O
overcorrects	O
for	O
bias	O
,	O
because	O
it	O
conditions	O
on	O
different	O
selection	O
rules	O
from	O
those	O
being	O
actually	O
used	O
.	O

This	O
negative	O
bias	O
can	O
be	O
particularly	O
severe	O
when	O
the	O
ratio	O
of	O
the	O
stage	O
1	O
treatment	O
variances	O
is	O
greater	O
than	O
1	O
:	O
2	O
,	O
and	O
in	O
these	O
cases	O
,	O
the	O
MSE	O
of	O
the	O
Kimani	O
estimator	O
increases	O
above	O
the	O
UMVCUE	O
.	O

These	O
results	O
indicate	O
that	O
the	O
difference	O
between	O
the	O
selection	O
rules	O
(	O
and	O
hence	O
the	O
estimators	O
)	O
is	O
greatest	O
when	O
there	O
is	O
reason	O
to	O
believe	O
that	O
the	O
treatment	O
effect	O
variances	O
are	O
different	O
from	O
treatment	O
to	O
treatment	O
,	O
such	O
as	O
when	O
different	O
classes	O
of	O
drugs	O
are	O
being	O
tested	O
and	O
we	O
have	O
variance	O
estimates	O
from	O
pilot	O
studies	O
.	O

Hence	O
,	O
if	O
selection	O
is	O
based	O
the	O
standardised	O
treatment	O
differences	O
,	O
then	O
we	O
would	O
recommend	O
using	O
the	O
new	O
UMVCUE	O
,	O
because	O
it	O
is	O
unbiased	O
and	O
generally	O
has	O
a	O
lower	O
MSE	O
.	O

Note	O
that	O
our	O
new	O
estimator	O
complements	O
the	O
existing	O
Kimani	O
estimator	O
(	O
and	O
its	O
modification	O
).	O

Indeed	O
,	O
the	O
two	O
frameworks	O
are	O
answering	O
different	O
questions	O
because	O
of	O
the	O
different	O
selection	O
rules	O
being	O
used	O
.	O

We	O
also	O
showed	O
how	O
to	O
extend	O
our	O
framework	O
to	O
estimate	O
the	O
jth	O
‐	O
ranked	O
treatment	O
effect	O
for	O
j	O
>	O
1	O
,	O
in	O
contrast	O
to	O
the	O
Kimani	O
estimator	O
,	O
which	O
is	O
only	O
for	O
the	O
largest	O
treatment	O
difference	O
.	O

Our	O
extended	O
UMVCUE	O
can	O
then	O
be	O
applied	O
within	O
the	O
context	O
of	O
formal	O
hypothesis	O
testing	O
,	O
where	O
we	O
correct	O
for	O
multiplicity	O
with	O
the	O
closure	O
principle	O
.	O

For	O
simplicity	O
,	O
we	O
used	O
the	O
Bonferroni	O
correction	O
in	O
our	O
example	O
,	O
but	O
our	O
framework	O
could	O
also	O
be	O
extended	O
to	O
work	O
with	O
more	O
powerful	O
multiplicity	O
adjustment	O
methods	O
,	O
such	O
as	O
the	O
Simes	O
,	O
Holm	O
or	O
Hochberg	O
procedures	O
(	O
as	O
described	O
in	O
,	O
e	O
.	O
g	O
.	O
19	O
).	O

In	O
this	O
paper	O
,	O
we	O
only	O
looked	O
at	O
point	O
estimation	O
of	O
the	O
treatment	O
difference	O
.	O

However	O
,	O
in	O
practice	O
,	O
it	O
is	O
natural	O
to	O
also	O
seek	O
confidence	O
intervals	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

One	O
possibility	O
would	O
be	O
to	O
use	O
a	O
parametric	O
bootstrap	O
procedure	O
,	O
similar	O
to	O
that	O
described	O
in	O
20	O
and	O
21	O
.	O

Alternatively	O
,	O
it	O
might	O
be	O
possible	O
to	O
adapt	O
the	O
analytic	O
approach	O
of	O
Sampson	O
and	O
Sill	O
22	O
to	O
the	O
seamless	O
phase	O
II	O
/	O
III	O
trial	O
setting	O
.	O

A	O
limitation	O
of	O
our	O
work	O
is	O
that	O
we	O
assume	O
that	O
the	O
variance	O
of	O
the	O
treatment	O
differences	O
are	O
known	O
.	O

In	O
practice	O
,	O
if	O
we	O
have	O
individual	O
variance	O
estimates	O
for	O
each	O
treatment	O
arm	O
,	O
then	O
these	O
will	O
be	O
less	O
precise	O
than	O
a	O
pooled	O
estimate	O
.	O

In	O
order	O
to	O
correctly	O
account	O
for	O
this	O
,	O
one	O
avenue	O
of	O
research	O
is	O
to	O
extend	O
the	O
formulae	O
of	O
Cohen	O
and	O
Sackrowitz	O
8	O
,	O
who	O
derived	O
the	O
UMVCUE	O
in	O
the	O
independent	O
normal	O
setting	O
(	O
but	O
without	O
the	O
option	O
of	O
early	O
stopping	O
)	O
where	O
the	O
variances	O
are	O
unknown	O
and	O
have	O
to	O
be	O
estimated	O
.	O

A	O
possible	O
extension	O
is	O
to	O
consider	O
trials	O
where	O
there	O
is	O
early	O
stopping	O
for	O
efficacy	O
.	O

This	O
would	O
be	O
especially	O
compatible	O
with	O
much	O
of	O
the	O
literature	O
on	O
the	O
combination	O
test	O
approach	O
,	O
where	O
there	O
can	O
be	O
early	O
rejection	O
of	O
the	O
null	O
hypothesis	O
16	O
.	O

However	O
,	O
we	O
anticipate	O
that	O
the	O
UMVCUE	O
would	O
become	O
much	O
more	O
complex	O
in	O
this	O
setting	O
,	O
because	O
of	O
the	O
additional	O
restrictions	O
on	O
the	O
support	O
of	O
Y	O
j	O
.	O

Finally	O
,	O
it	O
is	O
an	O
open	O
question	O
whether	O
there	O
exist	O
UMVCUEs	O
for	O
the	O
treatment	O
differences	O
that	O
are	O
functions	O
of	O
all	O
of	O
the	O
data	O
(	O
X	O
,	O
Y	O
)	O
instead	O
of	O
just	O
(	O
X	O
,	O
Y	O
0	O
,	O
Y	O
j	O
).	O

If	O
such	O
estimators	O
do	O
exist	O
,	O
then	O
they	O
may	O
outperform	O
both	O
our	O
UMVCUE	O
and	O
the	O
Kimani	O
estimator	O
in	O
terms	O
of	O
MSE	O
.	O

